20465 ⎘
Medicinal preparations containing organic active ingredients; Eicosanoids, e.g. leukotrienes or prostaglandins having heterocyclic rings containing oxygen as the only ring hetero atom, e.g. thromboxanes having five-membered rings containing oxygen as the only ring hetero atom, e.g. prostacyclin
LIPOSOME COMPOSITIONS COMPRISING WEAK ACID DRUGS AND USES THEREOF
#2PROSTANOID RECEPTOR AGONISTS AS NON-TUBERCULOUS ANTI-MYCOBACTERIAL AGENTS
#3METHODS AND COMPOSITIONS FOR TREATING CHRONIC OBSTRUCTIVE PULMONARY DISEASE, ASTHMA, PNEUMONIA, BRONCHITIS, CYSTIC FIBROSIS, PULMONARY EDEMA, INTERSTITIAL LUNG DISEASE, SARCOIDOSIS, IDIOPATHIC PULMONARY FIBROSIS, ACUTE RESPIRATORY DISTRESS SYNDROME, PULMONARY ARTERIAL HYPERTENSION, ADN RESPIRATORY SYNCYTIAL VIRUS
#4PHARMACEUTICAL PREPARATION FOR IMPROVING ABSORPTION AND POSTPRANDIAL HYPOGLYCEMIC ACTION OF INSULIN
#5PROSTACYCLIN ANALOGUE FORMULATIONS
#6LIPOSOME COMPOSITIONS COMPRISING WEAK ACID DRUGS AND USES THEREOF
#7TREATMENT OF HFPEF IN POST-MENOPAUSAL WOMEN WITH AN SGC STIMULATOR
#8COMBINATION THERAPY FOR PULMONARY HYPERTENSION
#9Liposome compositions comprising weak acid drugs and uses thereof
#10METHODS FOR TREATING PULMONARY HYPERTENSION
#11Treatment of pulmonary arterial hypertension with prostacyclin-treated endothelial progenitor cells
#12CHIMERIC ANTIGEN RECEPTOR (CAR) T-CELL ADJUVANT THERAPIES
#13OSMOTIC DRUG DELIVERY SYSTEM
#14PHARMACEUTICAL PREPARATION FOR IMPROVING ABSORPTION AND POSTPRANDIAL HYPOGLYCEMIC ACTION OF INSULIN
#15DRUG THAT PREVENTS DIALYSIS SHIFT OR RENAL DEATH
#16PROSTACYCLIN ANALOGUE FORMULATIONS
#17COMPOSITIONS COMPRISING RARE GENETIC SEQUENCE VARIANTS ASSOCIATED WITH PULMONARY FUNCTION AND METHODS OF USE THEREOF FOR DIAGNOSIS AND TREATMENT OF ASTHMA IN AFRICAN AMERICAN PATIENTS
#18Compositions and methods for skin rejuvenation
#19INSULIN-LIKE GROWTH FACTOR AXIS PROTEINS AS CIRCULATING PULMONARY ARTERIAL HYPERTENSION BIOMARKERS
#20METHODS AND COMPOSITIONS FOR TREATING CHRONIC OBSTRUCTIVE PULMONARY DISEASE, ASTHMA, PNEUMONIA, BRONCHITIS, CYSTIC FIBROSIS, PULMONARY EDEMA, INTERSTITIAL LUNG DISEASE, SARCOIDOSIS, IDIOPATHIC PULMONARY FIBROSIS, ACUTE RESPIRATORY DISTRESS SYNDROME, AND PULMONARY ARTERIAL HYPERTENSION
#21PHARMACEUTICAL USE
#22COMBINATION THERAPY FOR PULMONARY HYPERTENSION
#23Compositions and methods for treating coronavirus infections
#24METHOD FOR TREATING CARDIOPULMONARY DISORDER
#25METHOD TO ENHANCE TISSUE REGENERATION
#26Treatment of pulmonary arterial hypertension with prostacyclin-treated endothelial progenitor cells
#27OSMOTIC DRUG DELIVERY SYSTEM
#28Composition comprising prostacyclin andor analogues thereof for treatment of acute critically ill patients
#29Method for inducing production of vascular endothelial growth factor
#30COMBINATION THERAPY FOR PULMONARY HYPERTENSION
#31OSMOTIC DRUG DELIVERY SYSTEM
#32Prostacyclin analogue formulations
#33Drug composition for angiogenesis therapy
#34Method of treating hypertension
#35Liposome compositions comprising weak acid drugs and uses thereof
#36Treatment of pulmonary arterial hypertension with mesenchymal stem cells
#37Genetically modified host organism for expressing an anthracyclinone analogue, method associated therewith, and synthetic nucleic acids
#38Treatment of pulmonary arterial hypertension with prostacyclin-treated endothelial progenitor cells
#39A COMPOSITION COMPRISING PROSTACYCLIN ANDOR ANALOGUES THEREOF FOR TREATMENT OF ACUTE CRITICALLY ILL PATIENTS
#40Pharmaceutical use
#41Composition comprising prostacyclin andor analogues thereof for treatment of acute critically ill patients
#42Methods and compositions for treating metabolic syndrome
#43Fortifier
#44Rapid-acting insulin compositions
#45Method to enhance tissue regeneration
#46Osmotic drug delivery system
#47Drug-eluting stent graft
#48Beraprost-containing patch
#49Composition for the treatment of cystic fibrosis
#50Rapid-acting insulin compositions
#51Osmotic drug delivery system
#52EP2 AND EP4 AGONISTS AS AGENTS FOR THE TREATMENT OF INFLUENZA A VIRAL INFECTION
#53Carrier-linked prostanoid prodrugs
#54Treatment of pulmonary arterial hypertension with mesenchymal stem cells
#55Treatment of pulmonary arterial hypertension with prostacyclin-treated endothelial progenitor cells
#56COMPOUNDS CAPABLE OF MODULATING/PRESERVING ENDOTHELIAL INTEGRITY FOR USE IN PREVENTION OR TREATMENT OF ACUTE TRAUMATIC COAGULOPATHY AND RESUSCITATED CARDIAC ARREST
#57Process for preparing synthetic prostacyclins
#58Methods for reducing body fat
#59Methods of identifying critically ill patients at increased risk of development of organ failure and compounds for the treatment hereof
#60Sustained release composition of prostacyclin
#61Nanoparticle containing prostaglandin Iderivative
#62Methods and compositions for treating metabolic syndrome
#63PROSTACYCLIN AND ANALOGS THEREOF ADMINISTERED DURING SURGERY FOR PREVENTION AND TREATMENT OF CAPILLARY LEAKAGE
#64Composition for the treatment of cystic fibrosis
#65Methods and compositions for modulating P300/CBP activity
#66Method for enhancing engraftment of haematopoetic stem cells
#67METHODS FOR TREATING PULMONARY HYPERTENSION
#68Treatment for pulmonary hypertension
#69METHODS OF TREATMENT OF PATIENTS AT INCREASED RISK OF DEVELOPMENT OF ISCHEMIC EVENTS AND COMPOUNDS HEREOF
#70Epoprostenol formulation and method of making thereof
#71EP2 and EP4 agonists as agents for the treatment of influenza a viral infection
#72COMPOSITION FOR THE TREATMENT OF CYSTIC FIBROSIS
#73DRUG COMPOSITION FOR ANGIOGENESIS THERAPY
#74NOVEL INHIBITORS OF HEPATITIS C VIRUS REPLICATION
#75NON-ACIDIC CYCLOPENTANE HEPTANOIC ACID, 2-CYCLOALKYL OR ARYLALKYL DERIVATIVES AS THERAPEUTIC AGENTS
#76Methods of identifying critically ill patients at increased risk of development of organ failure and compounds for the treatment hereof
#77Inhalable Formulations For Treating Pulmonary Hypertension And Methods Of Using Same
#78Treatment for pulmonary hypertension
#79Methods of treating pulmonary hypertension
#80Method to enhance tissue regeneration
#81METHOD FOR TREATING ABDOMINAL DISCOMFORT
#82Compositions and methods for angiogenic therapy utilizing genes encoding ets-1
#83Methods and compositions for modulating P300/CBP activity
#84Non-acidic cyclopentane heptanoic acid, 2-cycloalkyl or arylalkyl derivatives as therapeutic agents
#85Combination therapy for the treatment of chronic renal failure with an angiotensin II receptor antagonist and beraprost
#86EP2 and EP4 agonists as agents for the treatment of influenza a viral infection
#87Therapeutic agent and treatment method for ameliorating uremia
#88Epoprostenol formulation and method of making thereof
#89Methods and compositions for treating pulmonary hypertension and related diseases and disorders
#90Oral sustained release pharmaceutical composition
#91Osmotic drug delivery system
#92Uses of prostacyclin analogs
#93Fortifier
#94Inhalable formulations for treating pulmonary hypertension and methods of using same
#95Treatment of female sexual dysfunction with vasoactive intestinal polypeptide agonists
#96Use of orally available prostacyclin derivatives for the production of a pharmaceutical agent for treating diseases that are associated with bone marrow edemas
#97Compound for treatment of external secretion disorders
#98As-needed administration of an androgenic agent to enhance female desire and responsiveness